Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema

Inclusion Criteria: * Clinical diagnosis of type 1 or type 2 DM * DME with central involvement (\> 300 µm in the central subfield on spectral-domain optical coherence tomography \[SD-OCT\], in the study eye * ETDRS BCVA score of ≥ 20 letters read and ≤ 70 letters read in the study eye * Naïve to local pharmacologic treatment for DME in the study eye Exclusion Criteria: * IOP \> 21 mmHg in the study eye at Visit 1 (Day -30 to -1); subjects are not excluded if IOP is \<22 mmHg in the study eye with no more than 1 IOP lowering medication * Any previous treatment in the study eye with an ocular corticosteroid implant * Has significant media opacity precluding evaluation of retina and vitreous in the study eye. * History of glaucoma or optic nerve head change consistent with glaucoma damage * History of glaucoma surgery * History of clinically significant IOP elevation in response to corticosteroid treatment ("steroid responder")